Skip to main content
Novartis to seek FDA approval for new Cosentyx indication

Novartis announced it will seek approval for a fourth indication for its drug Cosentyx, or secukinumab, to treat axial spondyloarthritis. The company will use data from its late-stage PREVENT trial, which met the study's primary endpoint by achieving Assessment in SpondyloArthritis International Society 40% response in patients with non-radiographic axial spondyloarthritis, to support the FDA submission, and has also filed a marketing application with the European Medicines Agency for the approval of Cosentyx for nr-axSpA.

Full Story: